tetano
Editor, Senior Moderator
J Infect Dis
. 2023 Sep 22;jiad409.
doi: 10.1093/infdis/jiad409. Online ahead of print. Oral Favipiravir Exposure and Pharmacodynamic Effects in Outpatient Adults with Acute Influenza
Frederick G Hayden[SUP] 1 [/SUP], Robert P Lenk[SUP] 2 [/SUP], Carol Epstein[SUP] 2 [/SUP], Lih Lisa Kang[SUP] 3 [/SUP]
Affiliations
Background: The pharmacokinetics of oral favipiravir and the relationships of plasma concentrations to antiviral effects are incompletely studied in influenza.
Methods: Serial plasma samples were collected from adults with uncomplicated influenza who were randomized to favipiravir (1800 mg BID on day 1, 800 mg BID on days 2 to 5)(N = 827) or placebo (N = 419) in two phase 3 trials. Post hoc analyses assessed the frequency of reaching an average Cmin ≥20ug/ml, its association with antiviral efficacy, and factors associated with reduced favipiravir exposure.
Results: Wide inter-individual variability existed in favipiravir concentrations, and this regimen failed to reach an average Cmin >20ug/ml in 41-43% of participants. Those attaining this threshold showed greater reductions in nasopharyngeal infectious virus titers on treatment days 2 and 3 (approximately 0.3-0.4 log10TCID50/ml) and lower viral titer AUCs compared to those who did not. Those with average Cmin <20ug/ml had over 2-fold higher mean ratios of the metabolite T-705-M1 to favipiravir, consistent with greater metabolism, and were more likely to weigh >80 kg (61.5-64%).
Conclusions: Higher favipiravir levels with average Cmin >20ug/ml were associated with larger antiviral effects and more rapid illness alleviation compared to placebo and to favipiravir recipients with lower average Cmin values in uncomplicated influenza.
Keywords: antiviral effects; favipiravir; influenza; pharmacodynamics; pharmacokinetics.
. 2023 Sep 22;jiad409.
doi: 10.1093/infdis/jiad409. Online ahead of print. Oral Favipiravir Exposure and Pharmacodynamic Effects in Outpatient Adults with Acute Influenza
Frederick G Hayden[SUP] 1 [/SUP], Robert P Lenk[SUP] 2 [/SUP], Carol Epstein[SUP] 2 [/SUP], Lih Lisa Kang[SUP] 3 [/SUP]
Affiliations
- PMID: 37739792
- DOI: 10.1093/infdis/jiad409
Background: The pharmacokinetics of oral favipiravir and the relationships of plasma concentrations to antiviral effects are incompletely studied in influenza.
Methods: Serial plasma samples were collected from adults with uncomplicated influenza who were randomized to favipiravir (1800 mg BID on day 1, 800 mg BID on days 2 to 5)(N = 827) or placebo (N = 419) in two phase 3 trials. Post hoc analyses assessed the frequency of reaching an average Cmin ≥20ug/ml, its association with antiviral efficacy, and factors associated with reduced favipiravir exposure.
Results: Wide inter-individual variability existed in favipiravir concentrations, and this regimen failed to reach an average Cmin >20ug/ml in 41-43% of participants. Those attaining this threshold showed greater reductions in nasopharyngeal infectious virus titers on treatment days 2 and 3 (approximately 0.3-0.4 log10TCID50/ml) and lower viral titer AUCs compared to those who did not. Those with average Cmin <20ug/ml had over 2-fold higher mean ratios of the metabolite T-705-M1 to favipiravir, consistent with greater metabolism, and were more likely to weigh >80 kg (61.5-64%).
Conclusions: Higher favipiravir levels with average Cmin >20ug/ml were associated with larger antiviral effects and more rapid illness alleviation compared to placebo and to favipiravir recipients with lower average Cmin values in uncomplicated influenza.
Keywords: antiviral effects; favipiravir; influenza; pharmacodynamics; pharmacokinetics.